• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

ASCO Announces Its Own Trial


June 1, 2015.

The American Society of Clinical Oncology (ASCO) will run a trial of its enrolling patients with advanced cancers but a dearth of standard treatment options. The trial will offer molecularly-targeted cancer drugs contributed free of charge by participating pharma companies.

The Targeted Agent and Profiling Utilization Registry (TAPUR) study will give “real-world” data on best uses of these drugs outside of approved indications.

ASCO petitioned several companies to sign on. Five major companies, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, and Pfizer, so far, have agreed to participate by signing memoranda of understanding.

See the press release here.

Related Videos